Diffuse Large B-cell Lymphoma, Lymphoma, Non-Hodgkin Lymphoma
A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma of the Activated B-cell Subtype
Eligible for screening study DCP 001
EFFECTIVE IMMEDIATELY, Friday, August 24, 2018, A051301 will be temporarily
suspended to new patient pre-registration (Step 0). Eligible patients who are currently
pre-registered may proceed to registration (Step 1).
Site Delegation of Tasks Log required prior to registration of any patients.